Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02891603 · ClinicalTrials.gov registry record · Phase 1

A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression

A Phase 1 study of Graft Vs Host Disease and GvHD, sponsored by H. Lee Moffitt Cancer Center and Research Institute.

Completed
Registry status
Phase 1
Development phase
40
Enrollment target
2
Study locations

NCT02891603 is a Phase 1 study of Graft Vs Host Disease and GvHD that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 40 participants, below the 137-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (71% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02891603, a Phase 1 study of Graft Vs Host Disease and GvHD, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.

COMPLETED
Registry status
Phase 1
Development phase
40 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to examine a new approach to preventing a serious problem after transplant called graft vs. host disease (abbreviated as GVHD). This is a 3 arm sequential phase I/II, study of Pacritinib with Sirolimus and Tacrolimus (PAC/SIR/TAC) for the prevention of acute GVHD after matched related and unrelated allogeneic hematopoietic cell transplantation (alloHCT).

Conditions Studied

Graft Vs Host Disease GvHD

Interventions

  • DRUG Sirolimus
  • DRUG Pacritinib
  • DRUG Tacrolimus
  • PROCEDURE Allogenic hematopoietic cell transplant (alloHCT)

Study Locations (2)

Florida

  • H. Lee Moffitt Cancer Center and Research Institute - Tampa

Minnesota

  • University of Minnesota - Minneapolis

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2017-06-08
Est. Completion 2022-04-18
Phase Phase 1

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

502 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02891603

The ClinicalTrials.gov registry entry for NCT02891603 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 137-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (71% lower). The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Graft Vs Host Disease appearing as the primary indexed condition, and to 4 interventions - of which Sirolimus is the first listed.

NCT02891603 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Minnesota.

Frequently Asked Questions

What is clinical trial NCT02891603 about?

NCT02891603 is a clinical study titled "A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression". The purpose of this study is to examine a new approach to preventing a serious problem after transplant called graft vs. host disease (abbreviated as GVHD). This is a 3 arm sequential phase I/II, study of Pacritinib with Sirolimus and Tacrolimus (PAC/SIR/TAC) for the prevention of acute GVHD after ...

What is the current status of trial NCT02891603?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2017-06-08. Estimated completion is 2022-04-18.

What conditions does trial NCT02891603 study?

This clinical trial studies the following conditions: Graft Vs Host Disease, GvHD.

What interventions are being tested in trial NCT02891603?

The interventions under investigation include: Sirolimus (DRUG), Pacritinib (DRUG), Tacrolimus (DRUG), Allogenic hematopoietic cell transplant (alloHCT) (PROCEDURE).

Who is sponsoring clinical trial NCT02891603?

This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02891603 being conducted?

This trial has 2 study locations across Florida, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Graft Vs Host Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Graft Vs Host Disease

All registered trials for this condition

GvHD

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.